November 6, 2014, Billerica, MA — EMD Millipore, the Life Science division of Merck KGaA, Darmstadt, Germany, offers new data demonstrating improved performance for its guava easyCyte™ 12 flow cytometer, a simple and powerful benchtop method for multicolor flow cytometry. The system has been shown to detect particles as small as 0.2 μm, a significant improvement over typical flow cytometers.
This increase in performance gives researchers better sensitivity and resolution for their experiments. Improved sensitivity provides better separation, making gating and identifying dimmer populations easier. In addition, resolution down to 0.2 μm opens up new application areas, particularly for researchers analyzing small particles and beads, as well as studying bacteria or algae.
“EMD Millipore has recognized the need for an advanced generation of powerful benchtop flow cytometers to enable today’s researchers to measure multiple molecular pathways and biomarkers at a cellular level,” said Patrick Schneider, Ph.D., Head of EMD Millipore Bioscience Business Area. “Our new performance data clearly demonstrate that guava easyCyte™ 12 flow cytometers can provide better resolution than traditional systems on the market, allowing scientists to achieve very powerful cellular analysis right at the benchtop.”
The guava easyCyte™ 12 flow cytometer uses three excitation lasers to detect up to 12 parameters simultaneously, including 10 fluorescent colors plus forward and side scatter for size and granularity determination. The upgraded lasers and unique scanning technology reduce channel bleedover and significantly improve resolution. Single-sample and multi-sample processing options are offered, and high-throughput analysis is possible with robotic sample trays that automatically handle 96-well micro¬plates and up to 10 sample tubes. The new platform consumes less sample, generates less waste and is easier to maintain than traditional systems, enabling researchers to save time and money while conducting comprehensive cell analysis.
The system, capable of detecting mammalian and micro¬bial cells and beads, offers an intuitive interface at an affordable price for every laboratory budget. As with all of EMD Millipore’s guava easyCyte™ systems, a sample of fluorescently labeled cells is aspirated into a microcapillary flow cell, which eliminates the need for sheath fluid and provides absolute cell counts. In addition, the flow cell is self-aligning and user-replaceable, reducing downtime and service visits.
For more information, please visit www.emdmillipore.com/guava.
About EMD Millipore
EMD Millipore is the Life Science division of Merck KGaA, Darmstadt, Germany and offers a broad range of innovative, performance products, services and business relationships that enable our customers' success in research, development and production of biotech and pharmaceutical drug therapies. Through dedicated collaboration on new scientific and engineering insights, and as one of the top three R&D investors in the Life Science Tools industry, EMD Millipore serves as a strategic partner to customers and helps advance the promise of life science. Headquartered in Billerica, Massachusetts, the division has around 10,000 employees, operations in 66 countries and 2013 revenues of €2.6 billion.
About Merck KGaA, Darmstadt, Germany
Merck KGaA of Darmstadt, Germany, is a leading company for innovative and top-quality high-tech products in the pharmaceutical and chemical sectors. Its subsidiaries in Canada and the United States operate under the umbrella brand EMD. Around 39,000 employees work in 66 countries to improve the quality of life for patients, to further the success of customers and to help meet global challenges. The company generated total revenues of € 11.1 billion in 2013 with its four divisions: Biopharmaceuticals, Consumer Health, Performance Materials and Life Science Tools. Merck KGaA, Darmstadt, Germany is the world’s oldest pharmaceutical and chemical company – since 1668, the name has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70 percent interest, the founding family remains the majority owner of the company to this day.